SEC Form 4 · accession 0001193125-26-257344
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Shields
Officer — EVP, Global Operations
Period of report
Jun 3, 2026
Accepted (ET)
Jun 4, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jun 3, 2026 | M | 16,195 | — | A | 26,184 | D | |
| Ordinary SharesF1,F4 | Jun 3, 2026 | S | 16,195 | $32.87 | D | 9,989 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F5,F1 | — | Jun 3, 2026 | M | 16,195 | D | — | — | Ordinary Shares | 16,195 | 32,392 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- F4Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
- F5Restricted share units were granted on June 3, 2024, with 16,195 vested on each of June 3, 2025 and June 3, 2026, 16,195 vesting on June 3, 2027, and 16,197 vesting on June 3, 2028.